Keytruda Bladder Cancer Advisory Cmte. To Discuss Clinical Meaningfulness Of Complete Response Rate

 
• By Derrick Gingery

US FDA's questions about Keytruda's increased response rate in Merck's study compared to the historical control were raised in a new point-counterpoint advisory committee briefing document format.

Human Body Organs (Urinary Bladder). 3D
The only other treatment approved in the proposed high-risk bladder cancer indication is not in treatment guidelines due to lack of efficacy. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers